SCHEMBL25995159

SCHEMBL25995159

CC(C)(C)CCCc1cc(CCCC(C)(C)C)c(O)cc1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
TDP1 Q9NUW8 4/20 0.40
RAD52 P43351 2/20 0.40
RECQL P46063 2/20 0.40
THRB P10828 2/20 0.40
GAPDH P04406 1/20 0.40
APEX1 P27695 1/20 0.40
BLM P54132 1/20 0.40
MAPT P10636 4/20 0.39
ALOX15 P16050 3/20 0.39
KDM4E B2RXH2 3/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
AGO2 Q9UKV8 1/20 0.39
TYR P14679 3/20 0.38
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX5 P09917 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25995193 0.94 MEN1 (0.39) MEN1KMT2ATDP1RAD52RECQL
SCHEMBL25995075 0.93 MEN1 (0.41) MEN1KMT2ATDP1RAD52RECQL
SCHEMBL25995238 0.92 MEN1 (0.42) MEN1KMT2ATDP1RAD52RECQL
SCHEMBL25995264 0.92 MEN1 (0.42) MEN1KMT2ATDP1RAD52RECQL
SCHEMBL25995251 0.92 MEN1 (0.42) MEN1KMT2ATDP1RAD52RECQL
SCHEMBL25995225 0.92 MEN1 (0.42) MEN1KMT2ATDP1RAD52RECQL
SCHEMBL25995097 0.85 MEN1 (0.43) MEN1KMT2ATDP1RAD52RECQL
SCHEMBL25995102 0.85 MEN1 (0.43) MEN1KMT2ATDP1RAD52RECQL
SCHEMBL25995399 0.84 ALOX15 (0.37) MEN1KMT2ATDP1RAD52RECQL
SCHEMBL26062152 0.84 MEN1 (0.35) MEN1KMT2ATDP1RAD52RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11737995-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease ESPERVITA THERAPEUTICS, INC. (US) 2023-08-29 US disclosed
US-11737995-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease ESPERVITA THERAPEUTICS, INC. (US) 2023-08-29 US disclosed
US-11730712-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease ESPERVITA THERAPEUTICS, INC. (US) 2023-08-22 US disclosed
US-11730712-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease ESPERVITA THERAPEUTICS, INC. (US) 2023-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11737995-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease AHR, PKD1, CFTR MEN1 3434/4885KMT2A 1717/4885TDP1 4883/4885
US-11730712-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease CPT1A, PPARG, PC MEN1 3931/4885KMT2A 2272/4885TDP1 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.